BRPI0509271A - formas de dosagens farmacêuticas gastrorresistentes compreendendo ácido n-(2-(2-ftalimidaetóxi)-acetil-l-alanil-d-glutámico(lk-4 23) - Google Patents

formas de dosagens farmacêuticas gastrorresistentes compreendendo ácido n-(2-(2-ftalimidaetóxi)-acetil-l-alanil-d-glutámico(lk-4 23)

Info

Publication number
BRPI0509271A
BRPI0509271A BRPI0509271-0A BRPI0509271A BRPI0509271A BR PI0509271 A BRPI0509271 A BR PI0509271A BR PI0509271 A BRPI0509271 A BR PI0509271A BR PI0509271 A BRPI0509271 A BR PI0509271A
Authority
BR
Brazil
Prior art keywords
dosage forms
pharmaceutical dosage
alanyl
acetyl
phthalimideethoxy
Prior art date
Application number
BRPI0509271-0A
Other languages
English (en)
Inventor
Marija Bogataj
Ales Mrhar
Anton Lavric
Manica Cerne
Doris Tibaut
Anton Stalc
Uros Urleb
Tatjana Mateovic
Greta Cof
Janez Kerk
Rok Dreu
Fumio Yoneda
Shizuko Muraoka
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of BRPI0509271A publication Critical patent/BRPI0509271A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"FORMAS DE DOSAGENS FARMACêUTICAS GASTRORRESISTENTES COMPREENDENDO áCIDO N-(2-(2-FTALIMIDAE-TóXI)-ACETIL-L-ALANIL-D-GLUTãMICO (LK-423)". A presente invenção refere-se às formas de dosagens farmacêuticas que permite uma liberação alvejada e/ou controlada de uma substância ativa para as regiões selecionadas do trato gastrointestinal de humanos ou animais. As formas de dosagens farmacêuticas preferivelmente compreendem a substância ativa ácido N-(2-(2-ftalimidoetóxi)-acetil)-L-alanil-D-glutâmico (designado como LK 423). Os métodos de tratamento de doenças inflamatórias crónicas do trato gastrointestinal de humanos e/ou animais empregando-se as formas de dosagens farmacêuticas da invenção são descritos.
BRPI0509271-0A 2004-03-26 2005-03-24 formas de dosagens farmacêuticas gastrorresistentes compreendendo ácido n-(2-(2-ftalimidaetóxi)-acetil-l-alanil-d-glutámico(lk-4 23) BRPI0509271A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200400094 2004-03-26
PCT/EP2005/003175 WO2005092295A1 (en) 2004-03-26 2005-03-24 Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)

Publications (1)

Publication Number Publication Date
BRPI0509271A true BRPI0509271A (pt) 2007-09-04

Family

ID=34964906

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509271-0A BRPI0509271A (pt) 2004-03-26 2005-03-24 formas de dosagens farmacêuticas gastrorresistentes compreendendo ácido n-(2-(2-ftalimidaetóxi)-acetil-l-alanil-d-glutámico(lk-4 23)

Country Status (15)

Country Link
US (1) US20100183714A1 (pt)
EP (1) EP1734933B1 (pt)
JP (1) JP2007530492A (pt)
CN (1) CN1956707B (pt)
AR (1) AR048342A1 (pt)
AT (1) ATE468846T1 (pt)
AU (1) AU2005226927B2 (pt)
BR (1) BRPI0509271A (pt)
CA (1) CA2559685A1 (pt)
DE (1) DE602005021475D1 (pt)
MY (1) MY145329A (pt)
PE (1) PE20051163A1 (pt)
RU (1) RU2375047C2 (pt)
TW (1) TW200600121A (pt)
WO (1) WO2005092295A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101795675A (zh) * 2006-11-17 2010-08-04 达沃尔泰拉公司 使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送
US8273376B2 (en) 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
WO2009037264A2 (en) * 2007-09-17 2009-03-26 Da Volterra Colonic delivery of antimicrobial agents
RU2593939C2 (ru) 2008-11-13 2016-08-10 Ногра Фарма Лимитед Антисмысловые композиции и способы их получения и применения
WO2016196440A1 (en) * 2015-06-01 2016-12-08 Xeno Biosciences Inc. Methods and compositions to modulate the gut microbiota and to manage weight
WO2017223337A1 (en) * 2016-06-23 2017-12-28 Nutrivert Llc Methods to promote growth and improve feed conversion in animals
JP7750644B2 (ja) * 2016-11-09 2025-10-07 エンジーン，インコーポレイティド プログラム細胞死リガンド１の腸管発現
KR20190095936A (ko) * 2016-12-14 2019-08-16 프로제너티, 인크. 인테그린 저해제로의 위장관 질환의 치료
AU2017378393B2 (en) * 2016-12-14 2023-03-09 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
CN110072519A (zh) * 2016-12-14 2019-07-30 普罗根尼蒂公司 使用jak抑制剂治疗胃肠道疾病及装置
CN108968074B (zh) * 2018-06-06 2021-09-28 福建省农业科学院农业工程技术研究所 一种结肠靶向递送的银耳糖醛酸多糖-芙蓉李花青素复合物及其制备方法
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
PL4126040T3 (pl) 2020-03-26 2025-04-28 Nutrivert Inc. Lipofilowe enancjomery deacetyloglukozamino–muramylodipeptydu o aktywności przeciwzapalnej i wspomagającej wzrost

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU210497B (en) * 1990-05-04 1995-04-28 Perio Prod Ltd Process for production of modified pectin
JP2773959B2 (ja) * 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
SI9011830B (sl) * 1990-09-27 1999-12-31 Univerza V Ljubljani, Fakulteta Za Farmacijo Novi N-acildipeptidi, postopki za njihovo pripravo in farmacevtski pripravki, ki jih vsebujejo
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems

Also Published As

Publication number Publication date
CN1956707A (zh) 2007-05-02
AU2005226927B2 (en) 2010-09-23
EP1734933A1 (en) 2006-12-27
TW200600121A (en) 2006-01-01
AR048342A1 (es) 2006-04-19
ATE468846T1 (de) 2010-06-15
JP2007530492A (ja) 2007-11-01
CA2559685A1 (en) 2005-10-06
PE20051163A1 (es) 2006-02-21
US20100183714A1 (en) 2010-07-22
CN1956707B (zh) 2010-12-29
MY145329A (en) 2012-01-31
WO2005092295A1 (en) 2005-10-06
EP1734933B1 (en) 2010-05-26
RU2375047C2 (ru) 2009-12-10
RU2006137660A (ru) 2008-05-10
AU2005226927A1 (en) 2005-10-06
DE602005021475D1 (de) 2010-07-08

Similar Documents

Publication Publication Date Title
BRPI0411924A8 (pt) Métodos e dispositivos para oclusão de lúmens de corpo e/ou para fornecimento de agentes terapêuticos
CY1119148T1 (el) Φαρμακευτικες συνθεσεις και συναφεις μεθοδοι χορηγησης
EA200800798A1 (ru) Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха
FR15C0009I2 (fr) Compositions de gel phospholipide destinees a l'administration medicamenteuse et des methodes de traitement utilisant celles-ci
EA201100873A1 (ru) Пиридилоксииндолы - ингибиторы vegf-r2 и их применение для лечения заболевания
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
EA201101518A1 (ru) Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии
ATE466604T1 (de) Medizinische vorrichtung zur verabreichung therapeutischer wirkstoffe über unterschiedliche zeitabschnitte
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
CY2017014I1 (el) Φαρμακευτικοι συνδυασμοι που περιεχουν βενζοξαζινες για τη θεραπεια νοσων των αναπνευστικων οδων
EP2049137A4 (en) SALICYLANILIDES AS AMPLIFIERS OF THE ORAL RELEASE OF THERAPEUTIC PEPTIDES
EA201100814A1 (ru) Фармацевтические формы применения, содержащие нифедипин или низолдипин и антагонист ангиотензина-ii и/или диуретик
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
EA200800782A1 (ru) ПРОИЗВОДНЫЕ АМИДА И КАРБАМАТА N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗОЛО[4,5-c]ХИНОЛИН-1-IL]-1,1-ДИМЕТИЛЭТИЛ}МЕТАНСУЛЬФОНАМИДА И СПОСОБЫ
BRPI0606707A2 (pt) uréias dissubstituìdas como inibidores de quinase
UY30587A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasa s janus
EA201300125A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний желудочно-кишечного тракта функциональной этиологии
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
EP4329753A4 (en) PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
EA201590797A1 (ru) Препараты с модифицированным высвобождением опрозомиба
DK2229440T3 (da) Rekombinante elastase-proteiner og fremgangsmåder til fremstilling og anvendelse deraf
MY145329A (en) Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.